We are live on ! Find out more
LYRA

LYRA THERAPEUTICS INC

Delisted

LYRA was delisted on the 16th of March, 2026.

60 hedge funds and large institutions have $222M invested in LYRA THERAPEUTICS INC in 2023 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 21 increasing their positions, 3 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,600% more call options, than puts

Call options by funds: $1.27M | Put options by funds: $27K

600% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 3

229% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 7

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

78% more capital invested

Capital invested by funds: $125M → $222M (+$97.1M)

36% more funds holding

Funds holding: 4460 (+16)

0.32% more ownership

Funds ownership: 1.29%1.61% (+0.32%)

Holders
60
Holders Change
+16
Holders Change %
+36.36%
% of All Funds
0.87%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
23
Increased
21
Reduced
3
Closed
7
Calls
$1.27M
Puts
$27K
Net Calls
+$1.24M
Net Calls Change
+$283K
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
26
BlackRock
New York
$581K +$229K +1,266 +133%
State Street
27
State Street
Massachusetts
$572K +$51K +282 +15%
Jane Street
28
Jane Street
New York
$410K +$283K +1,565 New
6CM
29
683 Capital Management
New York
$366K +$253K +1,397 New
Northern Trust
30
Northern Trust
Illinois
$323K +$16.5K +91 +8%
Qube Research & Technologies (QRT)
31
Qube Research & Technologies (QRT)
United Kingdom
$291K +$189K +1,043 +1,580%
Two Sigma Advisers
32
Two Sigma Advisers
New York
$266K +$184K +1,014 New
Renaissance Technologies
33
Renaissance Technologies
New York
$230K -$21.4K -118 -12%
LCM
34
Laurion Capital Management
New York
$222K +$153K +848 New
SSA
35
Schonfeld Strategic Advisors
New York
$219K +$151K +834 New
Man Group
36
Man Group
United Kingdom
$199K +$138K +760 New
JP Morgan Chase
37
JP Morgan Chase
New York
$174K +$120K +662 +66,200%
Barclays
38
Barclays
United Kingdom
$172K +$119K +656 New
LBA
39
Letko, Brosseau & Associates
Quebec, Canada
$167K
CSS
40
Cubist Systematic Strategies
Connecticut
$155K +$107K +593 New
ECM
41
ExodusPoint Capital Management
New York
$152K +$105K +581 New
Balyasny Asset Management
42
Balyasny Asset Management
Illinois
$151K +$104K +576 New
Bank of New York Mellon
43
Bank of New York Mellon
New York
$97.6K
JF
44
Jump Financial
Illinois
$87.7K +$60.6K +335 New
Walleye Capital
45
Walleye Capital
New York
$78.6K +$54.3K +300 New
Goldman Sachs
46
Goldman Sachs
New York
$68.5K +$47.2K +261 New
TSS
47
Two Sigma Securities
New York
$66.9K +$46.1K +255 New
YIH
48
Y-Intercept (HK)
Hong Kong
$64.3K +$44.5K +246 New
DIM
49
DLK Investment Management
California
$62.9K +$43.4K +240 New
HWMT
50
Heritage Wealth Management (Texas)
Texas
$52.4K +$36.2K +200 New

LYRA Hedge Fund Activity: Q4 2023 in Review

60 of the 6,862 institutional investors tracked by Wall St. Rank reported a position in LYRA THERAPEUTICS INC (LYRA) for Q4 2023, worth a combined $222M — up 78% from $125M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new LYRA positions and 7 closed out — a net gain of 16 holders — while 21 added to existing stakes and 3 trimmed.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $10.9M. The largest seller was Soleus Capital Management, exiting entirely with an estimated $2.32M sold.

  • 60 institutional investors held LYRA THERAPEUTICS INC (LYRA) as of Q4 2023, up from 44 in Q3 2023.
  • Funds reported $222M of LYRA THERAPEUTICS INC stock for Q4 2023, up 78% quarter-over-quarter.
  • 23 funds opened new LYRA THERAPEUTICS INC positions in Q4 2023 and 7 closed out, a net change of +16 holders.
  • The largest LYRA THERAPEUTICS INC buyer in Q4 2023 was Point72 Asset Management, an estimated $10.9M added.
  • The largest LYRA THERAPEUTICS INC seller in Q4 2023 was Soleus Capital Management, an estimated $2.32M sold.

Based on aggregated 13F filings for Q4 2023.